Disc Medicine Statistics
Total Valuation
Disc Medicine has a market cap or net worth of $2.55 billion. The enterprise value is $1.85 billion.
Important Dates
The last earnings date was Tuesday, May 5, 2026, before market open.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Disc Medicine has 38.20 million shares outstanding. The number of shares has increased by 23.05% in one year.
| Current Share Class | 38.20M |
| Shares Outstanding | 38.20M |
| Shares Change (YoY) | +23.05% |
| Shares Change (QoQ) | +2.28% |
| Owned by Insiders (%) | 0.48% |
| Owned by Institutions (%) | 99.84% |
| Float | 33.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.71 |
| P/TBV Ratio | 3.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 24.00, with a Debt / Equity ratio of 0.05.
| Current Ratio | 24.00 |
| Quick Ratio | 23.45 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -74.49 |
Financial Efficiency
Return on equity (ROE) is -35.83% and return on invested capital (ROIC) is -23.46%.
| Return on Equity (ROE) | -35.83% |
| Return on Assets (ROA) | -22.67% |
| Return on Invested Capital (ROIC) | -23.46% |
| Return on Capital Employed (ROCE) | -36.82% |
| Weighted Average Cost of Capital (WACC) | 15.94% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.57M |
| Employee Count | 154 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Disc Medicine has paid $293,000 in taxes.
| Income Tax | 293,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +46.21% in the last 52 weeks. The beta is 2.14, so Disc Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 2.14 |
| 52-Week Price Change | +46.21% |
| 50-Day Moving Average | 65.60 |
| 200-Day Moving Average | 72.12 |
| Relative Strength Index (RSI) | 46.73 |
| Average Volume (20 Days) | 458,823 |
Short Selling Information
The latest short interest is 5.54 million, so 14.50% of the outstanding shares have been sold short.
| Short Interest | 5.54M |
| Short Previous Month | 5.24M |
| Short % of Shares Out | 14.50% |
| Short % of Float | 16.67% |
| Short Ratio (days to cover) | 13.79 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -264.75M |
| Pretax Income | -241.31M |
| Net Income | -241.60M |
| EBITDA | -264.40M |
| EBIT | -264.75M |
| Earnings Per Share (EPS) | -$6.60 |
Full Income StatementBalance Sheet
The company has $730.16 million in cash and $31.06 million in debt, with a net cash position of $699.10 million or $18.30 per share.
| Cash & Cash Equivalents | 730.16M |
| Total Debt | 31.06M |
| Net Cash | 699.10M |
| Net Cash Per Share | $18.30 |
| Equity (Book Value) | 688.43M |
| Book Value Per Share | 18.03 |
| Working Capital | 716.31M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$201.25 million and capital expenditures -$82,000, giving a free cash flow of -$201.34 million.
| Operating Cash Flow | -201.25M |
| Capital Expenditures | -82,000 |
| Depreciation & Amortization | 350,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -201.34M |
| FCF Per Share | -$5.27 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Disc Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.05% |
| Shareholder Yield | -23.05% |
| Earnings Yield | -9.46% |
| FCF Yield | -7.88% |
Analyst Forecast
The average price target for Disc Medicine is $98.00, which is 46.58% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $98.00 |
| Price Target Difference | 46.58% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
